Advertisement
OCUL Forex Haberleri
AffaMed Therapeutics Reports Positive Top-Line Results From Study Evaluating DEXTENZA
Biotechnology company AffaMed Therapeutics announced Tuesday positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.
RTTNews
|
576 gün önce
